Search for drugs:
Typing the drug name to query
FEBUXOSTAT
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Effect on Cardiac Repolarization:
- The effect of febuxostat on cardiac repolarization as assessed by the QTc interval was evaluated in normal healthy patients and in patients with gout. Febuxostat in doses up to 300 mg daily (3.75 times the maximum recommended daily dosage), at steady-state, did not demonstrate an effect on the QTc interval.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
6
24086
Other ADRs
9022
38372565
Odds Ratio = 1.06
Drug Property Information
ATC Code(s):
- M04AA03 - febuxostat
- M04AA - Preparations inhibiting uric acid production
- M04A - ANTIGOUT PREPARATIONS
- M04 - ANTIGOUT PREPARATIONS
- M - MUSCULO-SKELETAL SYSTEM
Active Ingredient:FEBUXOSTAT
Active Ingredient UNII:101V0R1N2E
Drugbank ID:DB04854
PubChem Compound:134018
CTD ID: D000069465
PharmGKB:PA165958521
CAS Number:144060-53-7
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
- 80.0 mg/day M04AA03
Chemical Structure: 
SMILE Code:
CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.